What is HC Wainwright’s Forecast for ACRV FY2029 Earnings?

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share estimates for Acrivon Therapeutics in a note issued to investors on Wednesday, March 26th. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($1.25) per share for the year. HC Wainwright has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.06.

Several other research firms also recently commented on ACRV. Cantor Fitzgerald reissued an “overweight” rating on shares of Acrivon Therapeutics in a research report on Wednesday. KeyCorp assumed coverage on Acrivon Therapeutics in a report on Friday, January 31st. They issued an “overweight” rating for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Acrivon Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $23.17.

Acrivon Therapeutics Stock Performance

NASDAQ:ACRV opened at $2.24 on Thursday. The company has a market capitalization of $69.74 million, a PE ratio of -0.83 and a beta of 0.85. Acrivon Therapeutics has a fifty-two week low of $2.14 and a fifty-two week high of $11.90. The company has a 50 day simple moving average of $5.35 and a two-hundred day simple moving average of $6.53.

Institutional Trading of Acrivon Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. American Century Companies Inc. lifted its holdings in shares of Acrivon Therapeutics by 14.2% in the 4th quarter. American Century Companies Inc. now owns 17,588 shares of the company’s stock valued at $106,000 after acquiring an additional 2,186 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Acrivon Therapeutics by 7.6% in the 4th quarter. Renaissance Technologies LLC now owns 49,400 shares of the company’s stock worth $297,000 after purchasing an additional 3,500 shares during the period. Barclays PLC raised its position in shares of Acrivon Therapeutics by 14.4% in the fourth quarter. Barclays PLC now owns 38,091 shares of the company’s stock valued at $228,000 after buying an additional 4,785 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Acrivon Therapeutics by 20.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 37,063 shares of the company’s stock valued at $223,000 after purchasing an additional 6,239 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Acrivon Therapeutics during the fourth quarter worth $40,000. Hedge funds and other institutional investors own 71.62% of the company’s stock.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.